Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
作者信息
Roth Patrick, Valavanis Antonios, Weller Michael
机构信息
Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.
Department of Neuroradiology, University Hospital Zurich, Switzerland.
出版信息
Neuro Oncol. 2017 Mar 1;19(3):454-456. doi: 10.1093/neuonc/now265.
Abstract
摘要
相似文献
1
Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
Neuro Oncol. 2017 Mar 1;19(3):454-456. doi: 10.1093/neuonc/now265.
2
Pseudoprogression: an indicator for cure in combined immunotherapy?
Immunotherapy. 2019 Sep;11(13):1087-1093. doi: 10.2217/imt-2019-0034. Epub 2019 Jul 30.
3
Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Acta Derm Venereol. 2019 Jan 1;99(1):107-108. doi: 10.2340/00015555-3028.
4
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.
Nat Med. 2019 Mar;25(3):462-469. doi: 10.1038/s41591-019-0349-y. Epub 2019 Feb 11.
5
Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy.
Int J Mol Sci. 2019 Jan 4;20(1):158. doi: 10.3390/ijms20010158.
6
Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma.
Blood. 2018 Jun 21;131(25):2856-2859. doi: 10.1182/blood-2018-03-841262. Epub 2018 May 3.
7
Outcomes of Australian patients receiving non-funded anti-PD-1 immune checkpoint inhibitors for non-melanoma cancers.
Asia Pac J Clin Oncol. 2018 Aug;14(4):337-342. doi: 10.1111/ajco.12867. Epub 2018 Mar 1.
8
Nivolumab-induced aplastic anemia: A case report and literature review.
J Oncol Pharm Pract. 2019 Jan;25(1):221-225. doi: 10.1177/1078155217726159. Epub 2017 Aug 21.
9
Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
Curr Probl Diagn Radiol. 2019 Mar-Apr;48(2):142-147. doi: 10.1067/j.cpradiol.2018.01.005. Epub 2018 Jan 31.
10
Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma.
Lancet Haematol. 2019 Jan;6(1):e2-e3. doi: 10.1016/S2352-3026(18)30210-2.
引用本文的文献
1
A new paradigm for immunotherapy in glioblastoma.
Nat Med. 2025 May;31(5):1404-1405. doi: 10.1038/s41591-025-03607-9.
2
Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth.
Sci Rep. 2024 Aug 8;14(1):18444. doi: 10.1038/s41598-024-67437-4.
3
Exploring MAP2K3 as a prognostic biomarker and potential immunotherapy target in glioma treatment.
Front Neurol. 2024 Jun 13;15:1387743. doi: 10.3389/fneur.2024.1387743. eCollection 2024.
4
Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.
Int J Mol Sci. 2024 May 26;25(11):5774. doi: 10.3390/ijms25115774.
5
A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.
Neurol Sci. 2024 Jun;45(6):2561-2578. doi: 10.1007/s10072-024-07350-w. Epub 2024 Feb 3.
6
ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.
Clin Cancer Res. 2024 Jan 17;30(2):379-388. doi: 10.1158/1078-0432.CCR-23-1889.
7
Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme.
Open Med (Wars). 2023 Jun 2;18(1):20230716. doi: 10.1515/med-2023-0716. eCollection 2023.
8
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.
J Clin Invest. 2023 Jan 17;133(2):e163447. doi: 10.1172/JCI163447.
9
Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Front Immunol. 2022 Aug 3;13:961933. doi: 10.3389/fimmu.2022.961933. eCollection 2022.
10
Regulation of temozolomide resistance via lncRNAs: Clinical and biological properties of lncRNAs in gliomas (Review).
Int J Oncol. 2022 Sep;61(3). doi: 10.3892/ijo.2022.5391. Epub 2022 Jul 7.
本文引用的文献
1
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.
Lancet Oncol. 2015 Nov;16(15):e534-e542. doi: 10.1016/S1470-2045(15)00088-1.
2
Immunotherapy for glioblastoma: concepts and challenges.
Curr Opin Neurol. 2015 Dec;28(6):639-46. doi: 10.1097/WCO.0000000000000249.
3
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Nat Rev Neurol. 2015 Sep;11(9):504-14. doi: 10.1038/nrneurol.2015.139. Epub 2015 Aug 11.
Zotero 插件